We found that IL-33 treatment reduced pro-inflammatory IL-1β, IL-6, and IL-23 and increased anti-inflammatory IL-4, IL-5, and IL-10 during CDI (Fig. 3d, e). Here, IL33 is linked to clostridium difficile infection.